● TIER 2 — Compoundable · emerging dataGRADE B (men)Reproductive hormones
Anastrozole & other AIs
Aromatase inhibitors. Research verification: Yes (TGA pending). 1 human study record(s) in the FitClinicMD studies database.
GOALS · Hormone optimization / menopause / low T
FDA status
Approved for breast cancer (anastrozole, letrozole, exemestane); off-label in men.
Compounding (503A/503B)
Approved generics.
DEA
Not controlled.
WADA (sport)
S4.1 Aromatase inhibitors
Mechanism
Block aromatase.
Human evidence · 1
Older men low T, n=69: anastrozole decreased spine BMD vs placebo. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels.
Reference only. This page summarizes publicly available regulatory and research information about Anastrozole & other AIs. It is not a prescription, an endorsement, or an offer to dispense, and regulatory status can change. Clinicians should verify current status before prescribing or compounding.